A Q1 trading update was published by the medical equipment manufacturers Smith+Nephew this morning. Despite the looming tariff issues, the company reaffirmed guidance and noted that margins were expected to improve, too and whilst headwinds persist from China, these are also noted as having passed their peak impact. The Smith and Nephew share price added more than 5% in early trade.
The FTSE-250 animal genetics company Genus issued a note to the market this morning, advising that the US regulator had approved its therapy for avoiding a disease known as PRRS in pigs. The company is also in advanced conversations with a number of other national regulators and presumably the expectation is that the US approval will make acceptance elsewhere more likely. The Genus share price was up 23% shortly after the open.
Keeping with a theme here and AIM listed Genincode which specialises in the genetic risk assessment of cardiovascular disease issued an update this morning, advising that the FDA in the US had rejected its latest submission. Whilst management believes that all points raised can be addressed, there can be no certainty that the information provided will be sufficient. A further update has been promised in the full year results due late next month. The Genincode share price was 39% lower on Thursday morning.
Most read news on Investegate this morning
Trading Statement - - Taylor Wimpey (TW.)
